Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NYSE:MDT - Medtronic Stock Price, Forecast & News

$120.32
+1.29 (+1.08 %)
(As of 01/22/2020 06:00 AM ET)
Add
Compare
Today's Range
$118.81
Now: $120.32▼
$120.51
50-Day Range
$111.03
MA: $114.74▼
$120.32
52-Week Range
$82.77
Now: $120.32▼
$120.50
Volume5.59 million shs
Average Volume3.08 million shs
Market Capitalization$161.27 billion
P/E Ratio34.77
Dividend Yield1.81%
Beta0.6
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. Read More…

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:MDT
Previous Symbol
CUSIP58505510
CIK1613103
Webhttp://www.medtronic.com/
Phone353-1438-1700

Debt

Debt-to-Equity Ratio0.49
Current Ratio2.77
Quick Ratio2.28

Price-To-Earnings

Trailing P/E Ratio34.77
Forward P/E Ratio21.49
P/E Growth2.89

Sales & Book Value

Annual Sales$30.56 billion
Price / Sales5.28
Cash Flow$7.35 per share
Price / Cash Flow16.38
Book Value$37.44 per share
Price / Book3.21

Profitability

EPS (Most Recent Fiscal Year)$5.22
Net Income$4.63 billion
Net Margins15.11%
Return on Equity14.52%
Return on Assets8.10%

Miscellaneous

Employees90,000
Outstanding Shares1,340,380,000
Market Cap$161.27 billion
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

MDT Rates by TradingView

(Ad)

Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Medtronic (NYSE:MDT) Frequently Asked Questions

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic declared a quarterly dividend on Monday, December 9th. Stockholders of record on Friday, December 27th will be given a dividend of $0.54 per share on Friday, January 17th. This represents a $2.16 annualized dividend and a dividend yield of 1.80%. The ex-dividend date of this dividend is Thursday, December 26th. View Medtronic's Dividend History.

How were Medtronic's earnings last quarter?

Medtronic PLC (NYSE:MDT) issued its quarterly earnings results on Tuesday, November, 19th. The medical technology company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The medical technology company earned $7.71 billion during the quarter, compared to the consensus estimate of $7.66 billion. Medtronic had a return on equity of 14.52% and a net margin of 15.11%. Medtronic's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.22 earnings per share. View Medtronic's Earnings History.

When is Medtronic's next earnings date?

Medtronic is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Medtronic.

What guidance has Medtronic issued on next quarter's earnings?

Medtronic updated its FY 2020 Pre-Market earnings guidance on Monday, November, 25th. The company provided EPS guidance of $$5.57-5.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $$5.56. The company issued revenue guidance of $$31.4-31.7 billion, compared to the consensus revenue estimate of $$31.48 billion.

What price target have analysts set for MDT?

21 equities research analysts have issued 1 year price targets for Medtronic's stock. Their forecasts range from $99.00 to $135.00. On average, they anticipate Medtronic's stock price to reach $119.90 in the next twelve months. This suggests that the stock has a possible downside of 0.3%. View Analyst Price Targets for Medtronic.

What is the consensus analysts' recommendation for Medtronic?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 4 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medtronic.

What are Wall Street analysts saying about Medtronic stock?

Here are some recent quotes from research analysts about Medtronic stock:
  • 1. Northland Securities analysts commented, "We continue to wait for a definitive breakout in key categories in terms of growth. In fairness, Medtronic continues to improve operational efficiencies." (8/21/2019)
  • 2. Needham & Company LLC analysts commented, "Market open, Ellex announced preliminary FY19 revenue below our expectations and IFRS EBITDA slightly narrower than our expectations. iTrack, 2RT and Tango lasers delivered FY19 y/y revenue growth, but overall growth was below our estimates. Ellex announced the appointment of Maria Maieli, current CFO, as Interim CEO. Ellex expects to release final F2H19 results on August 29, 2019." (7/23/2019)
  • 3. According to Zacks Investment Research, "The declining CRHF segment raises concern for Medtronic. Escalating costs and expenses continue to weigh on Medtronic’s bottom line. On a positve note, in the past year, shares of Medtronic outperformed its industry. The company is successfully registering sustainable growth across major groups and regions, in addition to displaying successful achievement of synergy targets. The company is focusing on geographical diversification of its businesses. This apart, the company has been seeing certain favorable developments in its Diabetes business. The updated 2019 guidance with raised EPS view increases investors’ confidence on the stock. Meanwhile, we are optimistic about the recently-closed acquisition of Mazor Robotics which is expected to fortify Medtronic's position in spine surgery." (5/20/2019)
  • 4. Barclays PLC analysts commented, "We now project $5.15 versus $5.12 consensus. Formal FY20 guidance will come in May but mgmt expressed comfort with the Street EPS estimate (per Refinitiv $5.44) which implies ~5.6% y/y growth off the revised mid- point for FY19. In Jan, mgmt said a higher tax rate could prompt EPS growth to be up to 250bp below its 8% long-range plan (LRP) CAGR target. Mgmt noted it is still working through its options for financial engineering. We think FY20 is likely a back- end loaded year given revenue cadence considerations (i.e. comps, new products launches) as well as FX impacts. We now est. $5.42 vs. $5.38 prior. Net/net, nothing materially changed our view. We think the valuation offers some upside and we rate MDT OW. That said, the upside case may take time to work out as execution confidence builds and many pipeline milestones are more 2020 events." (2/20/2019)

Has Medtronic been receiving favorable news coverage?

Media stories about MDT stock have trended somewhat negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medtronic earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the medical technology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Medtronic.

Who are some of Medtronic's key competitors?

What other stocks do shareholders of Medtronic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), Walt Disney (DIS), NVIDIA (NVDA), AbbVie (ABBV), Home Depot (HD), Cisco Systems (CSCO), Starbucks (SBUX), Intel (INTC) and CVS Health (CVS).

Who are Medtronic's key executives?

Medtronic's management team includes the folowing people:
  • Mr. Omar S. Ishrak, Chairman & CEO (Age 63)
  • Ms. Karen L. Parkhill, Exec. VP, CFO & Principal Accounting Officer (Age 54)
  • Mr. Bradley E. Lerman, Sr. VP, Gen. Counsel & Company Sec. (Age 61)
  • Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 57)
  • Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 58)

Who are Medtronic's major shareholders?

Medtronic's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.18%), PGGM Investments (0.09%), Hexavest Inc. (0.07%), Calamos Advisors LLC (0.06%), Zurcher Kantonalbank Zurich Cantonalbank (0.06%) and Gateway Investment Advisers LLC (0.04%). Company insiders that own Medtronic stock include Bradley E Lerman, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Karen L Parkhill, Michael J Coyle, Omar Ishrak, Richard H Anderson, Richard Kuntz and Robert John White. View Institutional Ownership Trends for Medtronic.

Which major investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Gateway Investment Advisers LLC, Assenagon Asset Management S.A., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Rhenman & Partners Asset Management AB, Hexavest Inc., Zurcher Kantonalbank Zurich Cantonalbank and Global Thematic Partners LLC. Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, Michael J Coyle, Richard Kuntz and Robert John White. View Insider Buying and Selling for Medtronic.

Which major investors are buying Medtronic stock?

MDT stock was acquired by a variety of institutional investors in the last quarter, including PGGM Investments, Dudley & Shanley Inc., Johanson Financial Advisors Inc., Centre Asset Management LLC, Nisa Investment Advisors LLC, Cardinal Capital Management, Central Bank & Trust Co. and Janney Montgomery Scott LLC. Company insiders that have bought Medtronic stock in the last two years include Karen L Parkhill, Omar Ishrak and Richard H Anderson. View Insider Buying and Selling for Medtronic.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $120.32.

How big of a company is Medtronic?

Medtronic has a market capitalization of $161.27 billion and generates $30.56 billion in revenue each year. The medical technology company earns $4.63 billion in net income (profit) each year or $5.22 on an earnings per share basis. Medtronic employs 90,000 workers across the globe.View Additional Information About Medtronic.

What is Medtronic's official website?

The official website for Medtronic is http://www.medtronic.com/.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]


MarketBeat Community Rating for Medtronic (NYSE MDT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,390 (Vote Outperform)
Underperform Votes:  763 (Vote Underperform)
Total Votes:  2,153
MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe MDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Trading based on a resistance level
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel